13F Pro13F Pro

SEC Form 4 reporting owner

Gordon Carl L

Gordon Carl L has filed 44 Form 4 transactions reported between November 21, 2025 and November 10, 2026, as Director of Electra Therapeutics, Inc., Director of ADARx Pharmaceuticals, Inc., Director of BlossomHill Therapeutics, Inc., Director of Scribe Therapeutics, Inc., Director of Compass Therapeutics, Inc. and Director of Keros Therapeutics, Inc..

Name as filed: GORDON CARL L

Follow Gordon Carl L and get an alert on every new Form 4

Gordon Carl L holds 6.5M shares of ADRX, worth $91.6M, 5.82% of the company.

As of their Sep 28, 2026 Form 4 (filed Sep 30, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $14.16 · 111.2M shares outstanding on Nov 6, 2026 · adjusted for stock splits since

Gordon Carl L holds 2.7M shares of BLSM, worth $39.1M, 8.54% of the company.

As of their Aug 10, 2026 Form 4 (filed Aug 12, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $14.41 · 31.8M shares outstanding on Nov 10, 2026

Gordon Carl L holds 2.2M shares of ETRA, worth $19.6M, 3.49% of the company.

As of their Nov 6, 2026 Form 4 (filed Nov 10, 2026) · the filing on SEC EDGAR · valued at the Nov 19, 2026 close of $8.94 · 62.9M shares outstanding on Nov 6, 2026

Holdings in 1 more company are listed under Roles and reported holdings below.

Open-market buys, 24 mo
$65.5M
23 lines
Open-market sales, 24 mo
None
reported
Companies
6
with Form 4 filings
Latest transaction
Nov 10, 2026
transaction date

Roles and reported holdings

  • ETRAElectra Therapeutics, Inc.
    Sep 21, 2026 – Nov 10, 2026

    Director

    See footnotes2,194,579 sh

    As of Nov 6, 2026 · Form 4

    Shares held, direct and indirect, ETRA, after each Form 4
    1.7M2.0M2.2MSep 21, 2026: 1.8M shares (Form 4)Nov 3, 2026: 2.1M shares (Form 4)Nov 6, 2026: 2.2M shares (Form 4)Sep 21, 2026Nov 6, 2026
    FilingShares afterChange
    Nov 6, 20262.2M+58K
    Nov 3, 20262.1M+379K
    Sep 21, 20261.8M—

    24 months: $24.3M bought

  • ADRXADARx Pharmaceuticals, Inc.
    Sep 28, 2026

    Director

    See footnotes6,470,585 sh

    As of Sep 28, 2026 · Form 4

    24 months: $16.1M bought

  • BLSMBlossomHill Therapeutics, Inc.
    Aug 6, 2026 – Aug 10, 2026

    Director

    See footnotes2,714,279 sh

    Also reports 23,904 Director Stock Option (Right to Buy), not counted as shares.

    As of Aug 10, 2026 · Form 4

    24 months: $10.0M bought

  • SCTXScribe Therapeutics, Inc.
    Jul 23, 2026 – Jul 27, 2026

    Director

    See footnotes1,348,825 sh

    Also reports 14,725 Stock Option (Right to Buy), not counted as shares.

    As of Jul 23, 2026 · Form 4

    24 months: $15.0M bought

  • CMPXCompass Therapeutics, Inc.
    Jan 2, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • KROSKeros Therapeutics, Inc.
    Nov 21, 2025

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

How their buys did since

23 open-market purchases against today’s price: +112.4% on average, +185.8% weighted by dollars spent.

DatePaidReturn
Nov 10, 2026ETRA$8.45+5.8%now $8.94
Nov 10, 2026ETRA$8.45+5.8%now $8.94
Nov 9, 2026ETRA$8.24+8.5%now $8.94
Nov 9, 2026ETRA$8.24+8.5%now $8.94
Nov 6, 2026ETRA$7.85+13.9%now $8.94
Nov 6, 2026ETRA$7.85+13.9%now $8.94
Nov 5, 2026ETRA$7.31+22.3%now $8.94
Nov 5, 2026ETRA$7.31+22.3%now $8.94
Nov 4, 2026ETRA$7.07+26.4%now $8.94
Nov 4, 2026ETRA$7.07+26.4%now $8.94
Nov 4, 2026ETRA$7.78+14.9%now $8.94
Nov 4, 2026ETRA$7.78+14.9%now $8.94
Nov 3, 2026ETRA$7.88+13.4%now $8.94
Nov 3, 2026ETRA$7.88+13.4%now $8.94
Nov 3, 2026ETRA$7.84+14.0%now $8.94
Nov 3, 2026ETRA$7.84+14.0%now $8.94
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 28, 2026ADRX$1.55split-adj.+816.2%now $14.16
Sep 21, 2026ETRA$15.00-40.4%now $8.94
Sep 21, 2026ETRA$15.00-40.4%now $8.94
Aug 10, 2026BLSM$16.00-9.9%now $14.41
Jul 27, 2026SCTX$15.00-11.9%now $13.22

Each purchase at the price on its Form 4, against the latest trade or close, adjusted for stock splits. Past returns say nothing about future ones.

Transaction history

All 44 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Nov 10, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC2,000$17K@ $8.45Form 4
Nov 10, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC20,700$175K@ $8.45Form 4
Nov 9, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC16,000$132K@ $8.24Form 4
Nov 9, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC4,000$33K@ $8.24Form 4
Nov 6, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC39,600$311K@ $7.85Form 4
Nov 6, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC9,816$77K@ $7.85Form 4
Nov 5, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC125,200$915K@ $7.31Form 4
Nov 5, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC30,891$226K@ $7.31Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC20,000$141K@ $7.07Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC5,000$35K@ $7.07Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC37,100$289K@ $7.78Form 4
Nov 4, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC9,267$72K@ $7.78Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC98,600$777K@ $7.88Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC24,400$192K@ $7.88Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC97,800$767K@ $7.84Form 4
Nov 3, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC24,313$191K@ $7.84Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC588,235$10.0M@ $17.00Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC, Chimovits Erez61,516$1.0M@ $17.00Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect256,448—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect513,067—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect1,333,975—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect7,127,019—Form 4
Sep 28, 2026ADRXDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC300,249$5.1M@ $17.00Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect564,187—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect769,601—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect2,000,962—Form 4
Sep 28, 2026ADRXDirectorConversion of derivativeCode C · indirect10,690,530—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,000,000$15.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect758,279—Form 4
Sep 21, 2026ETRADirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC333,333$5.0M@ $15.00Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,703,314—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect1,087,934—Form 4
Sep 21, 2026ETRADirectorConversion of derivativeCode C · indirect2,002,310—Form 4
Aug 10, 2026BLSMDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC625,000$10.0M@ $16.00Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,049,283—Form 4
Aug 10, 2026BLSMDirectorConversion of derivativeCode C · indirect1,039,996—Form 4
Aug 6, 2026BLSMGrant or awardCode A · direct23,904—Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect2,065,672—Form 4
Jul 27, 2026SCTXDirectorOpen-market purchaseCode P · indirectAlso reported by ORBIMED ADVISORS LLC1,000,000$15.0M@ $15.00Form 4
Jul 27, 2026SCTXDirectorConversion of derivativeCode C · indirect348,825—Form 4
Jul 23, 2026SCTXGrant or awardCode A · direct14,725—Form 4
Jan 2, 2026CMPXDirectorGrant or awardCode A · direct90,000—Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect74,465$1.3M@ $17.75Form 4
Nov 21, 2025KROSDirectorDisposition to issuerCode D · indirect140,057$2.5M@ $17.75Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares each ownership line is left at by the person’s latest Form 4, 4/A or 5: held directly, and through each trust or entity named on the filing. A second class of common stock that converts into the listed one counts as shares; options and restricted stock units are listed but not counted. Value uses the latest trade or close, and the share of the company uses the latest shares-outstanding count the company reported. Where a filing has not yet been read line by line, the figure comes from the latest direct and indirect lines that traded and is shown as “at least”.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.